The latest health and pharmaceuticals industry and company news and analysis from FriedlNews
Page 1/10

Austrian Health and Pharma Headlines

Boehringer Ingelheim Pharma Austrian Unit Ups 2015 Revenues

German pharma group Boehringer Ingelheim raised revenues by 5.5 percent to EUR 760.2 million (USD 861.5 million) in Austria as well as over 30 countries supervised from Vienna in 2015, the company said. Operating performance grew by 2.4 percent y/y to EUR 1.14 billion.

April 20, 2016

Uniqa Insurance's Private Hospital Investment Investigated by Supreme Court

Listed insurance group Uniqa saw the Austrian supreme court OGH look into the planned acquisition of 75 percent in Vienna-based private hospital Goldenes Kreuz, Uniqa's unit PremiQaMed's Barbara Werwendt told APA, confirming earlier information from the medical chamber.

April 5, 2016

Sanochemia Founder Moves to Supervisory Board

During the shareholder meeting of listed pharmaceutical company Sanochemia Pharmazeutika AG on March 16 the shareholders approved the change of function of company founder Werner Frantsits, who transfers from the CEO chair to supervisory board member seat, the company announced. Felix Epper is another new member of the supervisory board.

March 21, 2016

Valneva Records Impressive Revenue Hike

Valneva, the pharmaceutical group created after the merger of Austria’s Intercell and French firm Lyon double-listed in Paris and Vienna, recorded EUR 83.3 million (USD 93.9 million) in revenue last year, up from EUR 42.4 million in 2014. However, the company posted an only slightly reduced loss of EUR 20.6 million (2014: EUR 26.3 million), CEO Thomas Lingelbach says. He stresses the firm is on the right track to become an integrated vaccine-focused pharma business.

March 21, 2016

Borealis Invests EUR 80 Million in Linz

The plastics, chemicals and fertilizer producer Borealis, 36 percent-owned by oil group OMV, will carry out a multi-million investment program in its branch in Linz. By 2020 EUR 80 million will be invested in the modernization of facilities, as the company announced. Between 2010 and 2014 the company invested already EUR 145 million (USD 163.5 million).

March 18, 2016

Valneva Gets USD 42 Million Order from US Government

Biotechnology company listed in Vienna, Valneva (formerly Intercell) has received a USD 42million (EUR 37.81 million) order from the US government.

March 16, 2016

31 Percent of Austrian Pharmacies in the Red

31 percent of the 1,370 pharmacies in Austria closed 2015 on a loss. This was due to two factors coinciding: poor rates of return and low equity capital ratios, it follows from data of the Austrian Pharmacists’ Association (Österreichischer Apothekerverband) cited in Vienna during a press conference.

March 7, 2016

Healthcare Spending Rising Constantly

Austria spends more and more on healthcare. In 2014 healthcare expenditures reached EUR 36.25 billion (USD 40.6 billion). The spending climbs on average by five percent per person per year. In the years from 1990 to 2014 spending rose from 8.4 to 11 percent of the GDP per year, latest Statistik Austria data indicate.

February 16, 2016

Possible Zika Vaccine Boosts Valneva Share Performance

In hopes of the soon market launch of a vaccine against the Zika virus, investors went for shares of listed biotech firm Valneva, formerly Intercell. The shares of the French firm listed in Vienna had soared 12.4 percent to EUR 3.45 by. Four times more shares than usual had changed hands by the afternoon.

February 4, 2016

Life Sciences Field is Booming in Vienna

Nine percent revenue growth, five percent increase in the workforce and a large increase in business startups - Vienna as a location for life science businesses is attracting companies at a rate never seen before.

October 14, 2015